Late appearance and exacerbation of primary Raynaud’s phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients

详细信息    查看全文

• 作者：Slavica Pavlov-Dolijanovic (1)
  Nemanja S. Damjanov (2)
  Nada Z. Vujasinovic Stupar (2)
  Goran L. Radunovic (2)
  Roksanda M. Stojanovic (2)
  Dragan Babic (3)
  
• 关键词：Raynaud’s phenomenon ; Connective tissue disease ; Systemic sclerosis ; Outcome
• 刊名：Rheumatology International
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：33
• 期：4
• 页码：921-926
• 全文大小：187KB
• 参考文献：1. Maricq HR, Weinrich MC, Keil JE, LeRoy EC (1986) Prevalence of Raynaud’s phenomenon in the general population. J Chronic Dis 39:423-27 CrossRef
  2. Kallenberg CG (1991) Connective tissue disease in patients presenting with Raynaud’s phenomenon alone. Ann Rheum Dis 50:666-67 CrossRef
  3. Kallenberg CG (1992) Raynaud’s phenomenon as an early sign of connective tissue diseases. Vasa Suppl 34:25-8
  4. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthr Rheum 58:3902-912 CrossRef
  5. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (2006) Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthr Rheum 54:1974-981 CrossRef
  6. Ingegnoli F, Boracchi P, Gualtierotti R, Biganzoli EM, Zeni S, Lubatti C et al (2010) Improving outcome prediction of systemic sclerosis from isolated Raynaud’s phenomenon: role of autoantibodies and nailfold capillaroscopy. Rheumatology (Oxford) 49:797-05 CrossRef
  7. Pavlov-Dolijanovic S, Damjanov N, Stojanovic R, Vujasinovic Stupar N, Stanisavljevic D (in press) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a Follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheum Int. doi:10.1007/s00296-011-2109-2
  8. Kallenberg CG (1990) Early detection of connective tissue disease in patients with Raynaud’s phenomenon. Rheum Dis Clin N Am 16:11-0
  9. LeRoy EC, Medsger TA Jr (1992) Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 10:485-88
  10. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 15:202-05
  11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 25:1271-277 CrossRef
  12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 31:315-24 CrossRef
  13. Alarcon-Segovia D, Cardiel MH (1989) Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 16:328-34
  14. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403-07 CrossRef
  15. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sj?gren’s syndrome: a revised version of the European criteria proposed by the American-Europe Consensus Group. Ann Rheum Dis 61:554-58 CrossRef
  16. Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17:615-20
  17. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthr Rheum 42:1309-311 CrossRef
  18. Gomariz EM, Del M, Guijo VP, Contreras AE, Villanueva M, Estévez EC (2002) The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice. J Rheumatol 29:326-30
  19. Balbir-Gurman A, Braun-Moskovici Y (2011) Scleroderma overlap syndrome. Isr Med Assoc J 13:14-0
  20. Campbell G (1994) Advances in statistical methodology for the evaluation of diagnosis and laboratory test. Stat Med 13:499-08 CrossRef
  21. Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud’s phenomenon in general practice. Br Med J 301:590-92 CrossRef
  22. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C et al (1997) Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol 24:879-89
  23. Brand FN, Larson MG, Kannel WB, Mc Guirk JM (1997) The occurrence of Raynaud’s phenomenon in a general population: the Framingham study. Vasc Med 2:296-01
  24. Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158:595-00 CrossRef
  25. Porter JM, Bardana EJ Jr, Baur GM, Wesche DH, Andrasch RH, Rosch J (1976) The clinical significance of Raynaud’s syndrome. Surgery 80:756-64
  26. Maricq HR, Weinberg AB, LeRoy EC (1982) Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud’s phenomenon. J Rheumatol 9:289-91
  27. Kallenberg CG, Pastoor GW, Wouda AA, The TH (1982) Antinuclear antibodies in patients with Raynaud’s phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 41:382-87 CrossRef
  28. Ohtsuka T, Tamura T, Yamakage A, Yamazaki S (1998) The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease. Br J Dermatol 139:622-29 CrossRef
  29. Wigley FM, Flavahan NA (1996) Raynaud’s phenomenon. Rheum Dis Clin N Am 22:765-81 CrossRef
  30. Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L et al (2008) Prognostic model based on nailfold capillaroscopy for identifying Raynaud’s phenomenon patients at high risk for the development of a scleroderma spectrum disorder. PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination). Arthr Rheum 58:2174-182 CrossRef
  31. Meli M, Gityelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153-58 CrossRef
  
• 作者单位：Slavica Pavlov-Dolijanovic (1)
  Nemanja S. Damjanov (2)
  Nada Z. Vujasinovic Stupar (2)
  Goran L. Radunovic (2)
  Roksanda M. Stojanovic (2)
  Dragan Babic (3)
  
  1. Institute of Rheumatology, Belgrade, Serbia
  2. University of Belgrade, Faculty of Medicine, Institute of Rheumatology, Belgrade, Serbia
  3. University of Belgrade, Faculty of Medicine, Institute of Medical Statistics and Informatics, Belgrade, Serbia
  

文摘

To assess the prognostic value of the age at onset of Raynaud’s (RP) and of a history of exacerbation of RP attacks for the development of connective tissue disease (CTD) in patients initially found to have primary Raynaud’s. 3,035 patients with primary RP (2,702 women and 333 men) were followed for an average of 4.8?years (range from 1 to 10?years). At baseline and every 6?months, they were screened for signs and symptoms of CTD. At 4.8?years of follow-up, 54.7?% patients remained as primary RP, 8.1?% had developed suspected secondary RP, and 37.2?% had developed a definite CTD. Primary RP patients had an earlier onset of RP (mean age of 32.2?years) than those with suspected (mean age 36.5?years, P?=?.007) or definite secondary RP associated with CTD (mean age of 39.8?years, P?=?.004). RP beginning before the age of forty was not significantly associated with the development of CTD. Conversely, the appearance of RP after the age of 40 was significantly associated with the development of CTD (P?=?.00001). Worsening of RP attacks predicted the development of CTD, especially systemic sclerosis (relative risk [RR] of 1.42), scleroderma overlap syndrome (RR of 1.18), and mixed CTD (RR of 1.18). Patients whose onset of RP occurred past 40?years of age and those with worsening RP attacks were at risk for the future development of CTD.